Find Funding Opportunities

NINDS Policy the Requirement Authorization the Food Drug Administration FDA) use Investigational Drug, Biologic Product Device a Clinical Trial Prior Submission an Application Notice Number: NOT-NS-11-018 Update: following update relating this announcement been issued: July 22, 2013 - Issuance PAR-13-278, NINDS Phase III Investigator-Initiated Efficacy Clinical Trials U01). March 13, 2012 - Notice NOT-NS-12-007. NINDS Policy Submission Applications Containing Clinical Trials. Key Dates Release Date: July 15, 2011 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to inform NINDS grant applicants that, beginning applications intended the September 25, 2011 due date beyond, following conditions related FDA regulations must met before NINDS allow submission an application involving clinical trial scientific technical review. Notice applies grant applications submitted under Exploratory Clinical Trials FOA PAR-10-199 http://grants.nih.gov/grants/guide/pa-files/PAR-10-199.html) the Phase III Clinical Trials FOA PAR-11-173 http://grants.nih.gov/grants/guide/pa-files/PAR-11-173.html) all subsequent NINDS FOAs where clinical trials FDA regulated interventions be proposed”. the time grant submission, applicants must provide documentation the FDA providing information one the following three scenarios: A)  protocol been submitted under open IND/IDE the IND/IDE not under full partial hold.  Under scenario, applicants must provide documentation such a proceed” email letter the FDA. B)  protocol been submitted under IND/IDE is full partial hold.  Under scenario applicants must provide full documentation the FDA the reasons hold the FDA recommendations. C)  protocol exempt an IND/IDE.  Under scenario applicants must provide copy the exemption letter the FDA. Applications do include information described under scenarios A), B), C) be withdrawn not reviewed.  Prior grant award NINDS require awardees do have previously documented study exemption provide documentation their IND/IDE remains open that has been placed under full partial hold. purposes this policy, clinical trial defined NIH policy http://grants.nih.gov/grants/policy/nihgps_2010/index. htm) a biomedical research study human subjects is designed answer specific questions biomedical interventions drugs, treatments, devices, new ways using known drugs, treatments, devices). Clinical trials used determine whether new interventions safe effective”. Inquiries Inquiries concerning policy should sent to: Scott Janis, Ph.D. Office Clinical Research National Institute Neurological Disorders Stroke Room 2170, MSC 9525 6001 Executive Blvd. Bethesda, MD 20892-9525 Telephone: 301) 496-9135 Fax: 301) 410-1080 Email: janiss@ninds.nih.gov D Elizabeth McNeil, M.D. MSc Office Clinical Research National Institute Neurological Disorders Stroke Room 2215, MSC 9520 6001 Executive Blvd. Bethesda, MD 20892-9520 Telephone: 301) 496-9135 Fax: 301) 410-1080 Email: mcneilde@ninds.nih.gov inquiries review issues contact: Chief, Scientific Review Branch National Institute Neurological Disorders Stroke Room 3201, MSC 9529 6001 Executive Blvd. Bethesda, MD 20892-9529 Telephone: 301) 496-9223 Fax: 301) 402-0182 Email: nindsreview@ninds.nih.gov

NINDS Parkinson's Disease Biomarkers Program Strategy Notice Number: NOT-NS-11-020 Update: following update relating this announcement been issued: September 1, 2011 - Notice NOT-NS-11-027. NINDS Request Information RFI) Creating Data Management Resource the Parkinson's Disease Biomarkers Program. Key Dates Release Date: July 15, 2011 Issued National Institute Neurological Disorders Stroke NINDS) Purpose Recently, has considerable progress our understanding the biology Parkinson’s disease.  However, inadequate measures disease progression, limited ability detect neurodegeneration prior the onset motor signs, the lack assays measure target engagement potential therapeutics currently impede therapy development.  overcome obstacles, NINDS intends establish Parkinson’s Disease Biomarkers Program PDBP).  goal this program to facilitate development neuroprotective agents slow halt progression Parkinson’s disease.  providing shared, high quality resources, PDBP program coordinate efforts multiple stakeholders.  will serve a multi-faceted platform for:  1) integrating existing biomarker efforts, 2) standardizing data collection management across efforts, 3) accelerating discovery validation new biomarkers, 4) fostering expanding collaborative opportunities all stakeholders.  will facilitate both clinical laboratory-based discovery projects designed lead the validation candidate markers pre-symptomatic diagnosis monitoring disease progression. markers ultimately critical designing effective Phase II III clinical trials.  Initially, PDBP have three major components: 1) Funding discovery projects designed identify promising biomarkers.  Examples such projects include development validation assays candidate analytes the of well-defined cohort studies identify clinical, pathological, imaging biomarkers. studies must include consent language allows broad public sharing biological samples deposition data the resources described below. 2) contract-based resource the banking sharing existing prospective biological samples meet stringent inclusion criteria be described the funding announcements.  3) Data Management Resource DMR).  resource receive, process, distribute standardized clinical, imaging, biological, molecular data the discovery other Parkinson’s biomarkers projects.  Both positive negative data be included the DMR. accelerate pace discovery, sharing data biological samples be core feature the PDBP.  program have clear sharing requirements data biological samples will promote sharing as close real time" possible.  collaboration the Parkinson's disease research community, NINDS integrate its PD biomarker projects within program. Inquiries Please direct inquiries to: Program Contact: Katrina Gwinn MD National Institute Neurological Disorders Stroke National Institutes Health 6001 Executive Blvd Room 2143 Bethesda, MD 20892 EXPRESS/COURIER:  Rockville, MD 20852 Phone: 301); 496-5745 Fax: 301) 401-5301 Email: gwinnk@ninds.nih.gov

NCCAM Termination Participation F31 Program Notice Number: NOT-AT-11-004 Key Dates Release Date:   June 30, 2011 Issued National Cancer Institute NCI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Drug Abuse NIDA) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) National Center Complementary Integrative Health NCCIH formerly NCCAM) Purpose is inform scientific community NCCAM no longer participate the Ruth L. Kirschstein National Research Service Awards NRSA) Individual Predoctoral Fellows Parent F31) Parent F31) PA-11-111) program. last receipt date new non AIDS F31 applications NCCAM August 8, 2011, September 7, 2011 AIDS related applications; last receipt date resubmissions non AIDS F31 applications NCCAM April 8, 2012 AIDS-related applications May 7, 2012. other aspects PA-11-111 remain unchanged. NCCAM continue offer support pre-doctoral students through Ruth L. Kirschstein National Research Service Awards Individual Predoctoral Fellowships Promote Diversity Health-Related Research Parent F31 - Diversity)(PA-11-112), Ruth L. Kirschstein NRSA Institutional Research Training Grants Parent T32) PA-11-184) the Ruth L. Kirschstein NRSA Short-Term Institutional Research Training Grants Parent T35) PA-11-185). Additionally, investigators continue include support pre-doctoral students NCCAM research project grants e.g., R01, U01, R21, P01, U19, etc.). Inquiries Please direct inquiries to: Partap S. Khalsa, DC, PhD, Acting Training Officer National Center Complementary Alternative Medicine 6707 Democracy Boulevard, Suite 401, Bethesda, MD 20892 301/594-3462 partap.khalsa@nih.gov www.nccam.nih.gov

Notice NIH Participation the National Robotics Initiative NRI) Notice Number: NOT-EB-11-006 Update: following update relating this announcement been issued: September 21, 2012 - Updates the NRI - Notice updates supersedes previous Guide Notice,NOT-EB-11-006. Notice NOT-EB-12-006. Key Dates Release Date: June 24, 2011 Issued National Institutes Health NIH)      National Institute Biomedical Imaging Bioengineering NIBIB)      National Institute Aging NIA)      Eunice Kennedy Shriver National Institute Child Health Human Development NICHD)     National Institute Nursing Research NINR)     National Institute Neurological Disorders Stroke NINDS)     National Center Research Resources NCRR) National Science Foundation NSF) National Aeronautics Space Administration NASA) U.S. Department Agriculture USDA) Purpose purpose this Notice to announce the NIH collaborating a multi-agency funding opportunity, National Robotics Initiative NRI) http://www.nsf.gov/nri), whose goal to accelerate development use robots the United States work beside, cooperatively with, people http://www.nsf.gov/publications/pub_summ.jsp?WT.z_pims_id=503641&ods_ke…; Innovative robotics research applications emphasizing realization such co-robots acting direct support a human supported multiple agencies the federal government including National Institutes Health NIH), National Science Foundation NSF), National Aeronautics Space Administration NASA), the U.S. Department Agriculture USDA). initiative facilitate development the next generation robotics, particularly co-robotics, encourage existing new communities focus innovative application areas. Collaboration between academic, industry, non-profit other organizations strongly encouraged establish better linkages between fundamental science technology development use.  NIH areas interest include, are limited to, robotics home care; personalized care special needs populations robotic wellness/health promotion; robot-assisted recovery; rehabilitation behavioral therapy; surgical interventional robots; high-throughput robotic technologies. Award Information Award sizes NIH funded research projects expected range approximately 100,000 250,000 per year direct costs, durations one five years.  award exceed 250,000 per year direct costs. Estimated program budget, number awards average award size duration subject the availability funds.  Determination awards based three criteria: 1) availability funds, 2) program priorities, 3) scientific merit. Subsequent grant administration procedures be accordance the policies the awarding Institute. Application Preparation Submission Instructions Applications submitted response this program announcement/solicitation should prepared submitted accordance the general guidelines contained the NSF Grant Proposal Guide GPG).  Applications must submitted the NSF, to NIH.  complete text the GPG available electronically the NSF Web Site at: http://nsf.gov/publications/pub_summ.jsp?ods_key=gpg.   Applicants reminded identify NSF program announcement number the program announcement block the NSF Cover Sheet Proposal the National Science Foundation.  Compliance this announcement critical determining relevant application processing guidelines.  Failure submit information delay processing. Budgetary Information Cost sharing not required applications submitted this funding opportunity. Budgets should include travel funds the PD/PI team members attend annual NRI Principal Investigators' meeting. NIH Process goal this activity to involve multiple agencies using application one review. meet NIH requirements, those applications are identified potential funding participating NIH Institutes Centers ICs), applicant organization be required submit R01application an NIH-approved format directly the Center Scientific Review http://www.csr.nih.gov/) the NIH.  PD/PIs invited submit NIH receive further information submission procedures the NIH. NIH application not allowed increase proposed budget change scientific content the application the converted submission the NIH. The summary statement be presented the involved IC's National Advisory Council the second level review. Subsequent the Council review, NIH ICs make funding determinations selected awards be made. Grant administration procedures NIH awardees, including those related New Early Stage Investigators http://grants.nih.gov/grants/new_investigators/) be accordance the policies NIH. Please note applications be submitted review the NSF November 3, 2011. Notification applications selected potential funding the participating NIH ICs be received the end March, 2012.  converted submission NIH be due April 11, 2012, will an extremely short conversion time.  applicant organization want work closely their Sponsored Programs Office assure timely submission during narrow submission window. earliest project start date be July 1, 2012. Inquiries Written telephone inquiries encouraged.  NIH Program contacts listed below. Please the NSF program announcement names contact information each the participating NSF Directorates http://www.nsf.gov/nri. John W. Haller, Ph.D., National Institute Biomedical Imaging Bioengineering 6707 Democracy Blvd., Bethesda, MD 20892 Telephone: 301.451.4780;  Fax: 301.480.4973 Email: hallerj@mail.nih.gov; http://www.nibib.nih.gov Lyndon Joseph, Ph.D Health Scientist Administrator Division Geriatrics Clinical Gerontology National Institute Aging, NIH, DHHS 7201 Wisconsin Avenue, Suite 3C307 Bethesda, MD 20892-9205 Telephone: 301-496-6926 Fax: 301-402-1784 Email: Josephlj@nia.nih.gov       www.nia.nih.gov Louis Quatrano, Ph. D. Program Director, BSRE, NCMRR Eunice Kennedy Shriver National Institute Child Health Human Development National Institutes Health 6100 Executive Blvd, Rm 2A03, MSC 7510, Bethesda, MD 20892-7510 Rockville, MD 20852 express/courier service) Office:  301-402-4221 Fax:  301-402-0832 Email: quatranl@mail.nih.gov   Paul A. Cotton, PhD, RD, Program Director National Institute Nursing Research NINR) 6701 Democracy Blvd, Ste. 710 Democracy Plaza Bethesda, MD 20892-4870 Courier zip: 20817) Phone: 301.402.6423 Fax:      301.451.5647 Email: Paul.Cotton@nih.gov;    http://www.ninr.nih.gov/ Daofen Chen,  Ph.D. Program Director Systems Cognitive Neuroscience National Institute Neurological Disorders Stroke NINDS/NIH) NIH Neuroscience Center, Room 2176 6001 Executive Boulevard Bethesda, MD 20892-9523 (FEDEX 20852) Phone: 301) 496-9964, FAX: 301) 402-1501 Email: daofen.chen@nih.gov  

Notice Clarification RFA-DK-11-010: Clinical Trial Planning Grants Type 1 Diabetes R34) Notice Number: NOT-DK-11-012 Key Dates Release Date: June 23, 2011 Issued National Institute Diabetes Digestive Kidney Diseases NIDDK) National Heart, Lung, Blood Institute NHLBI) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Neurological Disorders Stroke NINDS)) Purpose purpose this Notice to clarify funding applications submitted RFA-DK11-010: Clinical Trial Planning Grants Type Diabetes R34) of  future clinical trials may conducted awardees an R34 Clinical Trial Planning Grant under FOA. OLD LANGUAGE Section Funding Opportunity Description) FOA utilize NIH Clinical Trial Planning Grant R34) support development clinical trials individuals type 1 diabetes. Contingent the merit the proposed trials the availability funds, NIH anticipates funding up three full scale trials the funded R34 planning grants.  During early funding period the R34 grant, investigators have opportunity revise protocol based considerations raised peer review.  NIH then seek external input will guide priorities the support a limited number full clinical trials selected the funded R34 protocols.  Those clinical trials be conducted collaboration a single data coordinating center will awarded through future FOA. data coordinating center work R34 awardees finalize protocol budget, complete administrative tasks recruit clinical sites.  data coordinating center award provide support the conduct the selected trials.  Clinical trials developed under R34 grants are prioritized implementation through data coordinating center be appropriate support through funding sources mechanisms. NIDDK amending  Section I, paragraph four add following: Depending the merit cost the clinical trials proposed the applications, only single award be made, should most meritorious application a clinical trial utilize available funds. NIDDK also deleting following sentences: Those clinical trials be conducted collaboration a single data coordinating center will awarded through future FOA. data coordinating center work R34 awardees finalize protocol budget, complete administrative tasks recruit clinical sites.  data coordinating center award provide support the conduct the selected trials.   NIDDK adding sentence:  trials be funded through future FOA. NEW LANGUAGE Section I. Funding Opportunity Description, paragraph four FOA utilize NIH Clinical Trial Planning Grant R34) support development clinical trials individuals type 1 diabetes. Contingent the merit the proposed trials the availability funds, NIH anticipates funding up three full scale trials the funded R34 planning grants. Depending the merit cost the clinical trials proposed the applications, only single award be made, should most meritorious application a clinical trial utilize available funds. During early funding period the R34 grant, investigators have opportunity revise protocol based considerations raised peer review.  NIH then seek external input will guide priorities the support a limited number full clinical trials selected the funded R34 protocols.  trials be funded through future FOA. Clinical trials developed under R34 grants are prioritized implementation be appropriate support through funding sources mechanisms. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Teresa Jones, M.D. National Institute Diabetes Digestive Kidney Diseases 6707 Democracy Boulevard Bethesda, MD 20892 Telephone: 301) 435-2996 FAX: 301) 480-3503 E-mail: jonester@mail.nih.gov

Extension Expiration Dates PA-08-246 R01) PA-08-247 R21):  Chronic Fatigue Syndrome: Pathophysiology Treatment Notice Number: NOT-OD-11-083 Key Dates Release Date: June 10, 2011 Issued Office Research Women’s Health ORWH) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Environmental Health Sciences NIEHS) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) National Center Complementary Alternative Medicine NCCAM) National Center Research Resources NCRR) Office Dietary Supplements ODS) Purpose Notice extends expiration dates the Funding Opportunity Announcements FOA) PA-08-246 R01) PA-08-247 R21), Chronic Fatigue Syndrome: Pathophysiology Treatment.   new expiration date both FOAs January 8, 2012.  updated list Institute Center Science/Research contacts be posted the Trans-NIH ME/CFS Research Working Group website http://orwh.od.nih.gov/CSF%202011/resources.htm).  other aspects these FOAs remain unchanged. Inquiries Please direct inquiries to: Dennis F. Mangan, Ph.D. Chair, Trans-NIH ME/CFS Research Working Group Senior Research Advisor Office Research Women's Health, OD National Institutes Health 6707 Democracy Blvd., Suite 400 Bethesda, MD  20892-5484 Telephone:  301 496-9006 FAX:  301 402-1798 Email:  dennis.mangan@nih.gov

Notice Intent Publish Request Applications Stroke Prevention/Intervention Research Program SPIRP) U54) Notice Number: NOT-NS-11-017 Key Dates Release Date: June 7, 2011 Issued National Institute Neurological Disorders Stroke NINDS) Purpose National Institute Neurological Disorders Stroke NINDS) intends promote new initiative publishing Funding Opportunity Announcement FOA) solicit applications Stroke Prevention/Intervention Research Programs SPIRP); goal be develop interventions research have potential reduce stroke disparities minority communities through effective and culturally appropriate stroke prevention/intervention programs. Notice being provided allow potential applicants sufficient time develop meaningful collaborations responsive projects.  FOA expected be published Fall 2011 an expected receipt date Winter 2012. FOA utilize U54 activity code. U54 mechanism a solicited, multi-component award mechanism which substantial NIH scientific and/or programmatic involvement anticipated project completion.  Details the planned FOA provided below. Research Initiative Details Stroke the fourth leading cause death a leading cause long-term disability.  Stroke disparities a major public health problem the United States due the excess burden disease, excess mortality, worse outcome minority populations.  address these, innovative effective strategies directly reduce incidence, morbidity, mortality stroke racial/ethnic minority communities are within programmatic priority NINDS of interest. initiative directly responds the recommendations the NINDS Advisory Panel Health Disparities http://www.ninds.nih.gov/about_ninds/plans/NINDS_health_disparities_rpt…(pdf, 196 KB)) the Health Human Services plan addressing health disparities http://www.minorityhealth.hhs.gov/npa/files/Plans/HHS/HHS_Plan_complete…).  the purposes this announcement, stroke defined broadly may address ischemic hemorrhagic stroke disparities minority communities.  SPIRP application program) must contain least stroke prevention/intervention project up 3 additional projects directly related stroke disparities. additional projects range basic science through outcomes research.  projects should aim identify, monitor target biologic, environmental, social, healthcare system factors confer stroke its treatment disproportionately adversely underserved minority populations. nbsp;We anticipate trans-disciplinary multi-disciplinary teams be used implement SPIRP projects.  Projects also tools such community engagement, decision analysis, economic analysis, patient-centered outcomes enhance overall SPIRP. nbsp;Applications have cores are directly related the administration, training, scientific function the program. overall aims this initiative are: 1) develop effective evidence-based interventions prevention strategies designed decrease identified disparities stroke the potential be scaled-up regional national implementation; 2) support stroke disparities research projects are most likely targets next generation prevention/intervention programs that significantly further knowledge the research gaps stroke disparities; 3) provide formal, quality training junior investigators key stakeholders the implementation the prevention/intervention project.  Importantly, only prevention/intervention projects are culturally appropriate be considered.  Therefore, applicant should discuss methodology used address important element may include theoretical constructs population group specific socio-cultural bio-behavioral variables including health beliefs practices.    APPLICATIONS NOT BEING SOLICITED THIS TIME. Inquiries Please direct inquiries to: Salina Waddy, MD Program Director National Institute Neurological Disorders Stroke NINDS) 6001 Executive Boulevard, Room 2153  Bethesda, Maryland 20892 Phone: 301- 496-9135 FAX: 301) 402-1501 Email: waddysp@mail.nih.gov Website: http://www.ninds.nih.gov

Extension Expiration Date NIAID Funding Opportunity Announcement: Investigations Primary Immunodeficiency Diseases R01) PAR-08-206 Notice Number: NOT-AI-11-047 Key Dates Release Date: 25, 2011 Issued National Institute Allergy Infectious Diseases NIAID) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Neurological Disorders Stroke NINDS) Purpose Notice extends expiration date the Funding Opportunity Announcement:  Investigations Primary Immunodeficiency Diseases R01) PAR-08-206 http://grants.nih.gov/grants/guide/pa-files/PAR-08-206.html) one receipt date.  a result, FOA being extended September 8, 2011 January 8, 2012. other aspects this FOA remain unchanged. Inquiries contacts FOA any inquires.

Request Information: Whole Genome Sequencing, Data Analysis, Storage Annotation Notice Number:  NOT- NS-11-015   Key Dates Release Date:     11, 2011 Response Date:  30, 2011    Issued National Institute Neurological Disorders Stroke NINDS) Purpose is time sensitive Request Information RFI) issued the National Institute Neurological Disorders Stroke NINDS).  purpose the RFI to solicit information the research needs the NINDS community whole genome sequencing services accompanying data storage, analysis annotation services.  responses the RFI be collected evaluated Institute staff assess best meet current future needs whole genome sequencing it relates neurologic disease. Background Rapid significant changes technology continue advance our understanding human biology disease technological applications ranging single molecule whole genome approaches.  of technologies, massively parallel sequencing Next Generation Sequencing NGS) revolutionized our ability identify rare variants as yet unidentified Mendelian mutations related disease.  Although is clear NGS technology eventually dominate genomic research field, technological developments resulting reductions cost rapid increases sequencing speed improved accuracy.  reality these advancements sequencing technology enables re-sequencing the whole human genome be achieved within weeks instead months years unprecedented accuracy.  NGS technologies leading new strategies the understanding monogenic Mendelian diseases allowing identification causative mutations disorders were amenable linkage-based positional cloning Lupski J.R. et al., 2010]. Although cost availability services play role determining NGS approach exome verses whole genome), understanding underlying complexity the disease phenotype a key selection eventual success identifying causative mutation.  Since technologic advancements NGS been rapid, volume complexity the information captured through NGS challenges storage processing capabilities many laboratories institutions.  all roadblocks accessing NGS services processing NGS data removed, perhaps greatest challenge be analysis annotation data effectively differentiate between many rare benign variants detected novel genomic techniques disease causing mutations. RFI meant solicit information extramural research investigators regarding type availability projects can advanced through whole genome sequencing services.  RFI also solicits information institutional capabilities sequence storage, data analysis annotation.  Responses this RFI be reviewed NINDS staff will help inform complement assessment current future whole genome sequencing needs. RFI for planning purposes only, should be construed a solicitation applications proposals and/or an obligation any on part the United States Federal Government. Sequencing Services 1.  Describe whole genome sequencing services available planned your institution. 2.  Describe composition your research cohort e.g. small large families, population based) will utilize whole genome sequencing. 3.  Indicate you anticipate whole genome sequencing contribute your field research. 4.  Provide rationale choosing whole genome sequencing over whole exome sequencing. 5.  you plan utilize whole genome sequencing, many samples you sequence within next 12 months? will samples chosen? 6.  Outline plans your laboratory institution regarding storage capacity raw data generated whole genome sequencing. 7.  are plans your laboratory institution regarding analytical support sequence assembly, variant identification annotation? 8. Provide perspective the constraints regarding public sharing genomic sequences associated phenotype your research cohort. General Information 1.  Please identify nature your interest the area whole genome sequencing services i.e. you biomedical clinical researcher, member an advocacy community group, other?). 2.  you a member a particular advocacy professional organization, please indicate name the organization. 3.  Please indicate main area research interest. 4.  name 5.  email address * Note: of preceding fields optional. Proprietary, classified, confidential, sensitive information should be included your response.  Responses Responses must submitted electronically using web-based form http://www.ninds.nih.gov/funding/areas/neurodegeneration/RFI-for-Whole-… will accepted through 30, 2011.  Replies individual questions optional, the site permit anonymous responses. information provided be analyzed may appear various reports. Inquiries Please direct inquiries to: Margaret Sutherland, PhD Program Director, Neurodegeneration Cluster NINDS / NIH 6001 Executive Blvd., Rm 2222 Bethesda, MD 20892 Phone: 301-496-5680 Fax: 301-480-1080 E-mail: sutherlandm@ninds.nih.gov 

NINDS no longer utilize Mentored Research Scientist Development Award Parent K01; PA-11-190) support scientists re-entering research Notice Number: NOT-NS-11-013 Key Dates Release Date: April 11, 2011   Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to notify potential applicants for PA-11-190 formerly PA-10-056, is expiring 8, 2011), NINDS no longer accept new ReEntry K01 submissions.  NINDS accept resubmission applications only cycles II July 12) III November 12) 2011.  the future, NINDS use K01 support mechanism exclusively the purpose promoting diversity neuroscience research through PAR-09-065, is still active. Candidates interested support re-entry Neurological research should the NINDS Re-Entry supplement program an alternate opportunity: http://www.ninds.nih.gov/funding/areas/office_of_minority_health_and_re…. Inquiries Please direct inquiries to: Michelle Jones-London, Ph.D. Program Director Office Minority Health Research National Institute Neurological Disorders Stroke 6001 Executive Blvd NSC, Suite 2149, MSC 9535 Bethesda, MD 20892-9535 301-451-7966; Fax 301-594-5929 jonesmiche@ninds.nih.gov